E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effect of the mineralocorticoid receptor antagonist spironolactone on left ventricular mass index in end stage renal disease patients on hemodialysis. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the effect of spironolactone treatment on the following parameters/outcomes: cardiac function, serum potassium levels, blood pressure, hospitalization or death due to heart failure, kidney function, heart rate variability, cardiac arrhythmias, exercise capacity (6-minute walk test), vascular function (pulse wave analysis, flow-mediated dilatation, carotid intima-media thickness, carotid artery distensibility), body composition, quality of life and cardiovascular biomarkers, retinal capillary blood flow, retinal arteriolar wall structure |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Written informed consent
Age > 18 years
Hemodialysis treatment for at least 3 months
At least 3 dialysis sessions per week
|
|
E.4 | Principal exclusion criteria |
Contraindications for cardiac magnet resonance imaging (CMR)
Mineralocorticoid receptor antagonist treatment within the last 6 months
Estimated life expectancy < 12 months as judged by the nephrologist
History of hyperkalemia, defined as pre-dialysis potassium > 6.5 mmol/l occurring ≥ 3 times within the last 3 months prior to enrolment
High risk to develop hyperkalemia defined as pre-dialysis potassium > 6.0 mmol/l
Hypotension (systolic blood pressure < 100 mmHg)
Planned kidney transplantation (living donor) within the prospected study duration
Any acute illness within the last 4 weeks precluding a study participation as judged by the nephrologist
Non-amenorrheic women with child bearing potential without reliable contraception, pregnancy/lactation
Allergy/hypersensitivity to spironolactone
Non-compliance suspected or demonstrated |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in left ventricular mass index (LVMi) measured by cardiac MRI |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, after 9 months treatment. |
|
E.5.2 | Secondary end point(s) |
Cardiac function parameters (cardiac volumes, systolic and diastolic function, cardiac output) measured by CMR and echocardiography
Pre-dialysis serum potassium levels
Frequency of hyperkalemic episodes (potassium ≥ 6.5 mmol/l)
Office and 24h blood pressure
Clinical measures of heart failure severity (New York Heart Association (NYHA) functional class, 6 minute walk test)
Cardiac death and/or hospitalization due to heart failure (combined endpoint)
Residual kidney function (urine volume, creatinine-, urea-clearance, electrolyte excretion)
Heart rate variability (ECG)
Arterial stiffness (pulse wave analysis (PWA))
Carotid intima media thickness (CIMT)
Carotid artery distensibility (CD)
Flow-mediated dilatation (FMD) of the brachial artery
Body composition (bioimpedance spectroscopy)
Biomarkers of fibrosis, inflammation and heart failure
Quality of life
Adherence to study medication
retinal capillary blood flow, retinal arteriolar wall structure (scanning laser Doppler flowmetry) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
after a treatment duration of 9 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
4-6 weeks after the last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |